



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#10

IN RE APPLICATION OF

CHENG, ET AL.

APPLICATION NO: 10/081,969

FILED: FEBRUARY 22, 2002

FOR: NOVEL ONCOLYTIC ADENOVIRAL VECTORS

Confirmation No. 4496

Art Unit: 1636

Examiner: Marvich, Maria

Atty. Docket: 4-31704A

RECEIVED

MAY 14 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).


The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Bldg. 430
Research Triangle Park, NC 27709-2257
(301) 258-4832


Douglas Golightly
Patent Agent
Reg. No. 51,244

Date: May 6, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CHENG, ET AL.

APPLICATION NO: 10/081,969

FILED: FEBRUARY 22, 2002

FOR: NOVEL ONCOLYTIC ADENOVIRAL VECTORS

Confirmation No. 4496

Art Unit: 1636

Examiner: Marvich, Maria

Atty. Docket: 4-31704A

RECEIVED

MAY 14 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449. A copy of the reference is enclosed herewith.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

05/12/2003 CNGUYEN 00000067 190134 10081969


01 FC:1806 180.00 CH

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080
(301) 258-4832


Douglas Golightly
Patent Agent
Reg. No. 51,244

Date: May 6, 2003



1636/17

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Marcia Rossell
Type or print name

Marcia Rossell
Signature

May 6, 2003
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Confirmation No. 4496

CHENG, ET AL.

Art Unit: 1636

APPLICATION NO: 10/081,969

Examiner: Marvich, Maria

FILED: FEBRUARY 22, 2002

Atty. Docket: 4-31704A

FOR: NOVEL ONCOLYTIC ADENOVIRAL VECTORS

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RECEIVED

MAY 14 2003

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

Enclosed please find the following:

- a. Supplemental Information Disclosure Statement (1 page);
- b. PTO Form 1449 (1 page) with cited reference;
- c. Fee Letter for Information Disclosure Statement; and
- d. Return postcard.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080
(301) 258-4832

Douglas Golightly
Douglas Golightly
Patent Agent
Reg. No. 51,244

Date: May 6, 2003